Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard(Unknown), Е. О. Филиппова, Søren Lindberg(Novo Nordisk (Denmark)), Srecko Tusek, Ewa Skokowska, Luis De Loredo, Alberto Di Carlo, Zsolt Gaál, Eduard Montanya(Institut d'Investigació Biomédica de Bellvitge), Triantafyllos Didangelos, Pablo Jordão Alcântara Cruz, Davide Lauro(University of Rome Tor Vergata), Julio Rosenstock(Velocity Clinical Research (United States)), Marianne Bach Treppendahl(Novo Nordisk (Denmark)), Alessandra Gambineri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Teresa Stasinska, Silvio Buscemi, Győző Kocsis, Zsolt Sudár, Cecilia Luquez, Janusz Gumprecht(Medical University of Silesia), Chaicharn Deerochanawong(Rajavithi Hospital), Gerasimos Karousos, Małgorzata Arciszewska, Luís Henrique Santos Canani(Hospital de Clínicas de Porto Alegre), Svetlana Feofanova, Francesco Dotta(University of Chieti-Pescara), Péter Faludi, Zsolt Domboróczki, Tomislav Bulum, Emmanouil Pagkalos, Maria Somali, Marianna Maranghi, ANETTE L. SØNDERGAARD(Novo Nordisk (Denmark)), Dario Rahelić, Maria Alejandra Moisello, Ivana Sunic-Grcic, Branko Akrap, Piroska Kis-Gombos, Gustavo Akerman Augusto, Zoltán Márton, Krystyna Matuszewska, Christos Sampanis, Marian Benroubi, Ildiko Lingvay(Southwestern Medical Center), Marise Lazaretti Castro, Iakovos Avramidis
Cited by 442
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
|The Lancet Diabetes & Endocrinology|2018|758